NAV

N-acetyltyrosine

Identification

Summary

N-acetyltyrosineis an amino acid used in total parenteral nutrition.

Brand Names
Aminosyn二世7 %, Sulfite-free, Trophamine 10 %
Generic Name
N-acetyltyrosine
DrugBank Accession Number
DB11102
Background

N-acetyltyrosine, also referred to as N-acetyl-L-tyrosine, is used in place of as a tyrosine precursor.Tyrosine是一种非必需氨基酸,polar side group. N-acetyltyrosine is administered as parenteral nutrition or intravenous infusion due to its enhanced solubility compared to tyrosine2. It is typically administered as a source of nutritional support where oral nutrition is inadequate or cannot be tolerated.

Type
Small Molecule
Groups
Approved
Structure
 3D
Similar Structures
Weight
Average: 223.2252
Monoisotopic: 223.084457909
Chemical Formula
C11H13NO4
Synonyms
  • (+)-(2s)-2-(acetylamino)-3-(4-hydroxyphenyl)propanoic acid
  • (2s)-2-acetylamino-3-(4-hydroxyphenyl)propanoic acid
  • Acetyl tyrosine
  • L-N-acetyltyrosine
  • Melanowhite-A
  • N-acetyl-L-tyrosine
  • N-acetyl-tyrosine
  • N-acetyltyrosin
External IDs
  • 208-671-3
  • NSC-10853

Pharmacology

Indication

N-acetyltyrosine is indicated, in combination with several other amino acids and dextrose, as a peripherally administered source of nitrogen for nutritional support in patients with adequate stores of body fat in whom, for short periods, oral administration cannot be tolerated, is undesirable, or inadequateLabel.

It is also indicated, with other amino acids, 5-10% dextrose, and fat emulsion, for parenteral nutrition to preserve protein and reduce catabolism in stress conditions where oral administration is inadequateLabel.

When administered with other amino acids and concentrated dextrose, it is indicated for central vein infusion to prevent or reverse negative nitrogen balance in patients where the alimentary tract by the oral, gastrostomy, or jejestomy routes cannot or should not be used or in patients in which gastrointestinal absorption of protein is impaired, metabolic requirements for protein are substantially increased, or morbidity and mortality may be reduced by replacing amino acids lost from tissue breakdownLabel

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information oncontraindications & blackbox warnings, population restrictions, harmful risks, & more.
了解更多
Avoid life-threatening adverse drug events & improve clinical decision support.
了解更多
Pharmacodynamics

N-acetyltyrosine is used as a high solubility precursor toTyrosineused due toTyrosine's poor solubility2. It is deacetylated to formTyrosine.

Mechanism of action

Used as a source ofTyrosine. SeeTyrosinefor more information on its role and pharmacology.

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

N-acetyltyrosine is eliminated in the urine1. The extent of urinary elimination versus utilization in the tissues appears to be related to the rapidity of infusion. When infused slowly in standard doses as in the clinical setting, about 35% is excreted unchanged in the urine. When larger doses are infused rapidly, much higher amounts are excreted reaching values up to 56%3. In rat studies it was found that of the drug eliminated in the urine about 74% is present as unchanged N-acetyltyrosine and 23% is present as tyrosine2.

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including:blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
了解更多
Improve decision support & research outcomes with our structured adverse effects data.
了解更多
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRsBrowse all" title="" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug InteractionsLearn More" title="" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction
Integrate drug-drug
interactions in your software
Abacavir Abacavir马y decrease the excretion rate of N-acetyltyrosine which could result in a higher serum level.
Aceclofenac Aceclofenac may decrease the excretion rate of N-acetyltyrosine which could result in a higher serum level.
Acemetacin Acemetacin may decrease the excretion rate of N-acetyltyrosine which could result in a higher serum level.
Acetaminophen Acetaminophen may decrease the excretion rate of N-acetyltyrosine which could result in a higher serum level.
Acetazolamide Acetazolamide may increase the excretion rate of N-acetyltyrosine which could result in a lower serum level and potentially a reduction in efficacy.
Acetylsalicylic acid Acetylsalicylic acid may decrease the excretion rate of N-acetyltyrosine which could result in a higher serum level.
Aclidinium Aclidinium may decrease the excretion rate of N-acetyltyrosine which could result in a higher serum level.
Acrivastine Acrivastine may decrease the excretion rate of N-acetyltyrosine which could result in a higher serum level.
Acyclovir Acyclovir may decrease the excretion rate of N-acetyltyrosine which could result in a higher serum level.
Adefovir dipivoxil Adefovir dipivoxil may decrease the excretion rate of N-acetyltyrosine which could result in a higher serum level.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
了解更多
Food Interactions
No interactions found.

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image
Aminoplasmal Paed 10% Infusionslösung N-acetyltyrosine(1.3 g)+Acetylcysteine(0.7 g)+Alanine(15.9 g)+Arginine(9.1 g)+Aspartic acid(6.6 g)+Glutamic acid(9.3 g)+Glycine(2 g)+Histidine(4.6 g)+Isoleucine(5.1 g)+Leucine(7.6 g)+Lysine(8.8 g)+Methionine(2 g)+Phenylalanine(3.1 g)+Proline(6.1 g)+Serine(2 g)+Taurine(0.3 g)+Threonine(5.1 g)+Tryptophan(4 g)+Valine(6.1 g) Solution Parenteral B. Braun Melsungen Ag 2013-09-04 Not applicable Austria flag
AMINOPLASMAL-10% E INFUSION N-acetyltyrosine(1 g/l)+Acetylcysteine(0.5 g/l)+Alanine(13.7 g/l)+Arginine(9.2 g/l)+Asparagine(3.27 g/l)+Aspartic acid(1.3 g/l)+Glutamic acid(4.6 g/l)+Glycine(7.9 g/l)+Histidine(5.2 g/l)+Isoleucine(5.1 g/l)+Leucine(8.9 g/l)+Lysine hydrochloride(5.6 g/l)+Magnesium acetate(0.56 g/l)+Malic acid(1.01 g/l)+Methionine(3.8 g / l)+Ornithine hydrochloride(2.51 g/l)+Phenylalanine(5.1 g/l)+Potassium acetate(2.45 g/l)+Proline(8.9 g/l)+Serine(2.4 g/l)+Sodium acetate(3.95 g/l)+Sodium hydroxide(0.2 g/l)+Sodium phosphate, monobasic(1.4 g/l)+Threonine(4.1 g/l)+Tryptophan(1.8 g/l)+Tyrosine(0.3 g/l)+Valine(4.8 g/l) Injection Intravenous B. BRAUN SINGAPORE PTE LTD 1991-05-13 Not applicable
AMINOPLASMAL-5% E INFUSION N-acetyltyrosine(0.35 g / 1000毫升)+Acetylcysteine(0.25 g/1000ml)+Alanine(6.85 g/1000ml)+Arginine(4.6 g/1000ml)+Asparagine(1.64 g/1000ml)+Aspartic acid(0.65 g/1000ml)+Glutamic acid(2.3 g/1000ml)+Glycine(3.95 g/1000ml)+Histidine(2.6 g/1000ml)+Isoleucine(2.55 g/1000ml)+Leucine(4.45 g/1000ml)+Lysine hydrochloride(2.8 g/1000ml)+Magnesium acetate(0.56 g/1000ml)+Malic acid(1.01 g/1000ml)+Methionine(1.9 g/1000ml)+Ornithine hydrochloride(1.25 g/1000ml)+Phenylalanine(2.55 g/1000ml)+Potassium acetate(2.45 g/1000ml)+Proline(4.45 g/1000ml)+Serine(1.2 g/1000ml)+Sodium acetate(3.95 g/1000ml)+Sodium hydroxide(0.2 g/1000ml)+Sodium phosphate, monobasic(1.4 g/1000ml)+Threonine(2.05 g/1000ml)+Tryptophan(0.9 g/1000ml)+Tyrosine(0.3 g/1000ml)+Valine(2.4 g/1000ml) Injection Intravenous B. BRAUN SINGAPORE PTE LTD 1991-05-13 Not applicable
Aminosyn二世 N-acetyltyrosine(270 mg / 100 mL)+Alanine(993 mg / 100 mL)+Arginine(1018 mg / 100 mL)+Aspartic acid(700 mg / 100 mL)+Glutamic acid(738 mg / 100 mL)+Glycine(500 mg / 100 mL)+Histidine(300 mg / 100 mL)+Isoleucine(660 mg / 100 mL)+Leucine(1000 mg / 100 mL)+Lysine acetate(1050 mg / 100 mL)+Methionine(172 mg / 100 mL)+Phenylalanine(298 mg / 100 mL)+Proline(722毫克/ 100毫升)+Serine(530 mg / 100 mL)+Threonine(400 mg / 100 mL)+Tryptophan(200 mg / 100 mL)+Valine(500 mg / 100 mL) Solution Intravenous Icu Medical Canada Inc 1987-12-31 Not applicable Canada flag
Aminosyn二世 N-acetyltyrosine(270 mg/100mL)+Alanine(993 mg/100mL)+Arginine(1018毫克/ 100毫升)+Aspartic acid(700 mg/100mL)+Glutamic acid(738 mg/100mL)+Glycine(500 mg/100mL)+Histidine(300 mg/100mL)+Isoleucine(660 mg/100mL)+Leucine(1000 mg/100mL)+Lysine acetate(1050 mg/100mL)+Methionine(172 mg/100mL)+Phenylalanine(298 mg/100mL)+Proline(722 mg/100mL)+Serine(530 mg/100mL)+Threonine(400 mg/100mL)+Tryptophan(200 mg/100mL)+Valine(500 mg/100mL) Injection, solution Intravenous Icu Medical Inc. 2019-11-01 Not applicable US flag
Aminosyn二世 N-acetyltyrosine(270 mg/100mL)+Alanine(993 mg/100mL)+Arginine(1018毫克/ 100毫升)+Aspartic acid(700 mg/100mL)+Glutamic acid(738 mg/100mL)+Glycine(500 mg/100mL)+Histidine(300 mg/100mL)+Isoleucine(660 mg/100mL)+Leucine(1000 mg/100mL)+Lysine acetate(1050 mg/100mL)+Methionine(172 mg/100mL)+Phenylalanine(298 mg/100mL)+Proline(722 mg/100mL)+Serine(530 mg/100mL)+Threonine(400 mg/100mL)+Tryptophan(200 mg/100mL)+Valine(500 mg/100mL) Injection, solution Intravenous Hospira, Inc. 2005-09-01 2017-12-01 US flag
Aminosyn二世 N-acetyltyrosine(405 mg / 100 mL)+Alanine(1490 mg / 100 mL)+Arginine(1527 mg / 100 mL)+Aspartic acid(1050 mg / 100 mL)+Glutamic acid(1107 mg / 100 mL)+Glycine(750 mg / 100 mL)+Histidine(450 mg / 100 mL)+Isoleucine(990 mg / 100 mL)+Leucine(1500 mg / 100 mL)+Lysine acetate(1575 mg / 100 mL)+Methionine(258 mg / 100 mL)+Phenylalanine(447 mg / 100 mL)+Proline(1083 mg / 100 mL)+Serine(795 mg / 100 mL)+Threonine(600 mg / 100 mL)+Tryptophan(300 mg / 100 mL)+Valine(750 mg / 100 mL) Solution Intravenous Icu Medical Canada Inc 1995-12-31 Not applicable Canada flag
Aminosyn二世 N-acetyltyrosine(405 mg/100mL)+Alanine(1490 mg/100mL)+Arginine(1527 mg/100mL)+Aspartic acid(1050 mg/100mL)+Glutamic acid(1107 mg/100mL)+Glycine(750 mg/100mL)+Histidine(450 mg/100mL)+Isoleucine(990 mg/100mL)+Leucine(1500 mg/100mL)+Lysine acetate(1575 mg/100mL)+Methionine(258 mg/100mL)+Phenylalanine(447 mg/100mL)+Proline(1083 mg/100mL)+Serine(795 mg/100mL)+Threonine(600 mg/100mL)+Tryptophan(300 mg/100mL)+Valine(750 mg/100mL) Injection, solution Intravenous Hospira, Inc. 1991-12-19 2023-12-01 US flag
Aminosyn二世 N-acetyltyrosine(270 mg/100mL)+Alanine(993 mg/100mL)+Arginine(1018毫克/ 100毫升)+Aspartic acid(700 mg/100mL)+Glutamic acid(738 mg/100mL)+Glycine(500 mg/100mL)+Histidine(300 mg/100mL)+Isoleucine(660 mg/100mL)+Leucine(1000 mg/100mL)+Lysine acetate(1050 mg/100mL)+Methionine(172 mg/100mL)+Phenylalanine(298 mg/100mL)+Proline(722 mg/100mL)+Serine(530 mg/100mL)+Threonine(400 mg/100mL)+Tryptophan(200 mg/100mL)+Valine(500 mg/100mL) Injection, solution Intravenous Hospira, Inc. 1991-12-19 2013-09-01 US flag
Aminosyn二世 N-acetyltyrosine(230 mg/100mL)+Alanine(844 mg/100mL)+Arginine(865 mg/100mL)+Aspartic acid(595 mg/100mL)+Glutamic acid(627 mg/100mL)+Glycine(425 mg/100mL)+Histidine(255 mg/100mL)+Isoleucine(561 mg/100mL)+Leucine(850 mg/100mL)+Lysine acetate(893 mg/100mL)+Methionine(146 mg/100mL)+Phenylalanine(253 mg/100mL)+Proline(614 mg/100mL)+Serine(450 mg/100mL)+Threonine(340 mg/100mL)+Tryptophan(170 mg/100mL)+Valine(425 mg/100mL) Injection, solution Intravenous Hospira, Inc. 2005-07-29 2017-06-01 US flag

Categories

Drug Categories
Chemical TaxonomyProvided byClassyfire
Description
This compound belongs to the class of organic compounds known as tyrosine and derivatives. These are compounds containing tyrosine or a derivative thereof resulting from reaction of tyrosine at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Tyrosine and derivatives
Alternative Parents
Phenylalanine and derivatives/N-acyl-L-alpha-amino acids/Phenylpropanoic acids/Amphetamines and derivatives/1-hydroxy-2-unsubstituted benzenoids/Acetamides/Secondary carboxylic acid amides/Monocarboxylic acids and derivatives/Carboxylic acids/Organopnictogen compounds
show 4 more
Substituents
1-hydroxy-2-unsubstituted benzenoid/3-phenylpropanoic-acid/Acetamide/Amphetamine or derivatives/Aromatic homomonocyclic compound/Benzenoid/Carbonyl group/Carboxamide group/Carboxylic acid/Hydrocarbon derivative
show 15 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
L-tyrosine derivative, N-acetyl-L-amino acid (CHEBI:21563)
Affected organisms
Not Available

Chemical Identifiers

UNII
DA8G610ZO5
CAS number
537-55-3
InChI Key
CAHKINHBCWCHCF-JTQLQIEISA-N
InChI
InChI=1S/C11H13NO4/c1-7(13)12-10(11(15)16)6-8-2-4-9(14)5-3-8/h2-5,10,14H,6H2,1H3,(H,12,13)(H,15,16)/t10-/m0/s1
IUPAC Name
(2 s)2-acetamido-3-(4-hydroxyphenyl)propanoic acid
SMILES
CC(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O

References

General References
  1. Hoffer LJ, Sher K, Saboohi F, Bernier P, MacNamara EM, Rinzler D: N-acetyl-L-tyrosine as a tyrosine source in adult parenteral nutrition. JPEN J Parenter Enteral Nutr. 2003 Nov-Dec;27(6):419-22. [Article]
  2. Im HA, Meyer PD, Stegink LD: N-acetyl-L-tyrosine as a tyrosine source during total parenteral nutrition in adult rats. Pediatr Res. 1985 Jun;19(6):514-8. [Article]
  3. Magnusson I, Ekman L, Wangdahl M, Wahren J: N-acetyl-L-tyrosine and N-acetyl-L-cysteine as tyrosine and cysteine precursors during intravenous infusion in humans. Metabolism. 1989 Oct;38(10):957-61. [Article]
Human Metabolome Database
HMDB0000866
PubChem Compound
68310
PubChem Substance
347827896
ChemSpider
61606
BindingDB
50043802
RxNav
31005
ChEBI
21563
ChEMBL
CHEMBL65543
ZINC
ZINC000000156395
PDBe Ligand
3NF
PDB Entries
3nfz
FDA label
Download (1 MB)
MSDS
Download (35.9 KB)

Clinical Trials

Clinical TrialsLearn More" title="" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count
3 Completed Treatment Infants, Premature/Low Birth Weight Infants/Newborn Infants/Sepsis/Small for Gestational Age Infants 1
2 Active Not Recruiting Treatment Carcinoid Tumors/Medulloblastomas/Neuroblastoma (NB)/Neuroendocrine Tumors 1
Not Available Completed Treatment Malignancies, Hematologic 1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Form Route Strength
Solution Parenteral
Injection Intravenous 0.5 g/l
Injection Intravenous 0.25 g/1000ml
Liquid Intravenous
Injection, solution Intravenous
Solution Intravenous
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Property Value Source
melting point (°C) 149-152 MSDS
Predicted Properties
Property Value Source
Water Solubility 2.51 mg/mL ALOGPS
logP 1.03 ALOGPS
logP 0.59 Chemaxon
logS -2 ALOGPS
pKa (Strongest Acidic) 3.67 Chemaxon
pKa (Strongest Basic) -2 Chemaxon
Physiological Charge -1 Chemaxon
Hydrogen Acceptor Count 4 Chemaxon
Hydrogen Donor Count 3 Chemaxon
Polar Surface Area 86.63 Å2 Chemaxon
Rotatable Bond Count 4 Chemaxon
Refractivity 56.54 m3·mol-1 Chemaxon
Polarizability 22.25 Å3 Chemaxon
Number of Rings 1 Chemaxon
Bioavailability 1 Chemaxon
Rule of Five Yes Chemaxon
Ghose Filter Yes Chemaxon
Veber's Rule No Chemaxon
MDDR-like Rule No Chemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Spectrum Spectrum Type Splash Key
GC-MS Spectrum - GC-MS (3 TMS) GC-MS splash10-02t9-1790000000-9484167b29dc57768b67
GC-MS Spectrum - GC-MS (2 TMS) GC-MS splash10-004i-1921000000-91d4d68bb345a8a8a747
Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available
GC-MS Spectrum - GC-MS GC-MS splash10-02t9-1790000000-9484167b29dc57768b67
GC-MS Spectrum - GC-MS GC-MS splash10-004i-1921000000-91d4d68bb345a8a8a747
MS/MS Spectrum - Quattro_QQQ 10V, Positive LC-MS/MS splash10-0059-0900000000-1a298550f3c63022066c
MS/MS Spectrum - Quattro_QQQ 25V, Positive LC-MS/MS splash10-000i-1900000000-489314daf5773f9fa91e
MS/MS Spectrum - Quattro_QQQ 40V, Positive LC-MS/MS splash10-0006-9300000000-3a02844e3f23883a2818
Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
1H NMR Spectrum 1D NMR Not Applicable
[1H,13C] 2D NMR Spectrum 2D NMR Not Applicable

Drug created at December 03, 2015 16:51 / Updated at June 12, 2020 16:53